Preclinical animal testing is used to give reasonable data prior to early feasibility testing in people and human clinical trials in order to show that new technologies and therapies are safe and effective. During the nonclinical phase, animal models can help support and develop medical product development. Animal models that are well-designed can solve regulatory safety issues and provide further de-risking during product validation. Animal models can be used to evaluate minimum viable products and prototypes, which can help with quality assurance and compliance. To avoid superfluous preclinical research, a roadmap for product innovation strategies (regulatory, reimbursement) must be developed. Preclinical animal model safety and efficacy data are an important aspect of medical device development and are required to make these judgments. Before moving on to costly human trials, this can assist evaluate if the gadget is effectively tackling an actual need. Academic centers, which are generally based in linked veterinary medicine schools, provide unique resources that might help academic entrepreneurs fill this preclinical need.
Title : The era of artificial intelligence (AI) and its use in regenerative medicine
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cells for human disease modelling and potential for tissue repair
Patrizia Ferretti, UCL Great Ormond Street Institute of Child Health, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : The role of gingival fibroblasts in periodontal diseases and regeneration
Katarzyna Gawron, Medical University of Silesia in Katowice, Poland
Title : Personalized and Precision Medicine (PPM): A unique healthcare model via pathology-related modelling and bi-odesign-inspired translational applications for the next gen-eration of human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation